Revolutions Medical Corporation ("Revmed" or the "Company") (OTCBB:RMCP), has signed an agreement of understanding for the setting up of a manufacturing facility in Brazil to produce the RevVac safety syringe for domestic and global markets and to facilitate distribution throughout South America.
Santa Monica Pharmaceutica Ltda has been formed and funded for the specific purpose of manufacturing and distribution of the RevMed proprietary RevVac safety syringe.
"In Santa Monica Pharmaceutica Ltda, we could not have found a more committed strategic partner who shares our vision of reducing unnecessary accidental needle stick injuries and the promoting of healthcare safety. They also share our belief that our proprietary auto retractable vacuum safety syringe technology is the future and has many advantages over older auto retractable technologies currently available in the market place. Also, the commitment by the Brazilian state government legislating mandatory safety syringe, played a major part in our final decision to execute this strategic relationship in Brazil. I believe upon completion of final documents, the long anticipated launch of the mass production of our RevVac safety syringe, after the success of the pilot run announced in December, has finally arrived. We could not be more excited to be working in this strategic partnership with Santa Monica Pharmaceutica Ltda," states Ron Wheet CEO, RevMed.
Nick Ogle Commercial Director of Libra international states, "Since December when we were engaged by RevMed we have completed a stringent vetting process adhering to strict criteria in order to find the ideal strategic partner. The criteria included: commitment to a rapid production schedule, manufacturing expertise, distribution outlets and similar values and goals. The combination of RevMed's superior technology and attention to detail and Santa Monica Pharmaceutica Ltda's manufacturing capability and enthusiasm makes this the perfect strategic partnership."
Clive Davies Managing Director of Libra International, who now resides in Brazil states, " Not only is this a win, win situation for RevMed and Santa Monica but also for Brazil which has secured initial global production and all the prestige that comes with having beaten off stiff international competition for such a world class product."
Breaking through new research barriers with iPSC technology